Health Economic Evaluation of an Adapted Physical Activity Program for Women With Breast Cancer

NCT ID: NCT05949983

Last Updated: 2025-12-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

866 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-23

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Adapted physical activity (APA) was recognized as a non-drug therapy by the French Health Authority (HAS) in 2011. Very few studies have examined the efficiency of APA programs during the active phase of treatment in cancer patients. The investigators assumed that non-drug therapy such as APA could improve the quality of life and reduces health costs. The main objective of this study is to assess the efficiency of a standardized APA program, as compared to conventional management including simple recommendations for the practice of physical activity in women in phase active breast cancer treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Scientific rationale: The incidence of breast cancer in women is on the rise again over the period 2010-2018. The overall cost of cancer treatment is 16.8 billion euros, including 3.6 billion for drugs alone. The treatments are more and more prolonged, the proportion of anticancer drugs continues to increase with 10% of the amount reimbursed for drugs delivered in pharmacies in 2017.

Adapted physical activity (APA) was recognized as a non-drug therapy by the HAS in 2011. It reduces certain side effects of treatments, as well as certain symptoms linked to the catabolic activity of the disease such as: fat gain, loss of muscle mass, physical deconditioning, fatigue or pain. For breast cancer, a meta-analysis showed that APA following adjuvant therapy may have a beneficial effect on quality of life. The APA shows in particular for breast cancer, a reduction in all-cause mortality as well as specific mortality and a reduction in recurrence.The prescription of APA has been allowed since the 2016 health law but there is no coverage by the French national health insurance fund (CNAM) despite the benefits shown. APA is only accessible in a few centers in France that have chosen to offer it to patients, thus creating social inequalities in health.

Very few studies have examined the efficiency of APA programs during the active phase of treatment. They related to cohorts of 60 to 165 patients and uses different methods. The investigators decided to set up a study that can measure the efficiency of the standardized APA programs offered to patients diagnosed with breast cancer, assuming that non-drug therapy such as APA would improve the quality of life while reducing health costs.

Description of the procedures: The intervention consists of an initial consultation appointment with a medical check-up and physical tests, then inclusion in the standardized APA program for 6 months. The control group will be offered the same initial consultation appointment with medical check-up and physical tests and will receive recommendations for physical practice as well as a calendar of activities to be practiced independently for 6 months. Inclusion in the APA program will be offered one year after inclusion.

Follow-up: The data will be collected at T0, T + 3 months, T + 6 months, T + 9 months and T + 12 months in both arms. There will be 1 year of data analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Neoplasm

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Physical Activity Exercise Exercise Therapy Breast Neoplasms Medical costs Healthcare Costs

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

APA program Group

patients treated and monitored for breast cancer under the APA programme

Group Type EXPERIMENTAL

APA Program

Intervention Type OTHER

Patients treated and monitored for their breast cancer following the 6-month APA program.

Physical activity recommendation Group

patients treated and monitored for breast cancer who have received recommendations for physical activity

Group Type ACTIVE_COMPARATOR

Recommendations for physical activity

Intervention Type OTHER

Patients treated and monitored for their breast cancer who have received recommendations for physical activity as well as a 6-month activity schedule. To facilitate patient acceptance and participation in this study, patients who will be randomized to the control group will be offered to follow the APA program after one year of inclusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

APA Program

Patients treated and monitored for their breast cancer following the 6-month APA program.

Intervention Type OTHER

Recommendations for physical activity

Patients treated and monitored for their breast cancer who have received recommendations for physical activity as well as a 6-month activity schedule. To facilitate patient acceptance and participation in this study, patients who will be randomized to the control group will be offered to follow the APA program after one year of inclusion

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* women with breast cancer
* any type of breast cancer, all grades, all stages
* during treatment: surgery +/- chemotherapy +/- radiotherapy +/- hormone therapy

Exclusion Criteria

* World Health Organization (WHO) 4
* Unstable angina
* Uncontrolled Atrial fibrillation
* Uncontrolled high blood pressure
* Recent myocardial infarction or myocarditis or pericarditis or thromboembolic disease (less than 3 weeks)
* Aortic stenosis or valve disease to operate
* Cardiac or respiratory failure, with dyspnea at rest
* Symptomatic anemia, thrombocytopenia
* Lytic or painful bone metastases, Severe osteoporosis
* Severe infectious syndrome,
* Surgery in the last 3 weeks
* Extreme fatigue, sharp pain, dizziness, disturbance of consciousness, severe undernutrition
* Contraindication to the practice of an adapted physical activity programme
* Currently involved or exclusion period of a interventional study or adapted Physical Activity program
* Patient with protective measures (guardianship, curators, and deprivation of liberty).
* Pregnancy or breastfeeding
* Patient with severe functional limitations
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Toulouse

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marie-Eve Rougé-Bugat, MD

Role: PRINCIPAL_INVESTIGATOR

University Toulouse

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Marie-Eve Rougé-Bugat

Toulouse, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Marie-Eve Rougé-Bugat, MD

Role: CONTACT

Phone: 5 61 80 01 23

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marie-Eve Rougé-Bugat, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RC31/21/0339

Identifier Type: -

Identifier Source: org_study_id

2022-A00017-36

Identifier Type: OTHER

Identifier Source: secondary_id